Work

Pan-cancer analysis of KEAP1 mutations as biomarkers for immunotherapy outcomes

Year: 2020
Type: article
Abstract: Immune checkpoint inhibitors (ICIs) that target programmed cell death protein 1 (PD-1) and its ligand (PD-L1), or cytotoxic T lymphocyte antigen-4 (CTLA-4) elicit durable antitumor responses in multiple cancer types. Yet, only a minority of patients could derive clinical benefit (1).
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: diamond
OpenAlex ID: W2993652631
FWCI: 3.709
Cites: 10
Cited by: 67
Related to: 10